心血管指南

订阅

MedSci主页 / 所有栏目 / 心血管指南

2019 ESC立场声明：利尿剂在充血性心力衰竭中的应用

2019-01-01 欧洲心脏病学会 Eur J Heart Fail. 2019 Jan 1.

利尿剂充血性心力衰竭

2019年1月，欧洲心脏病学会(ESC)心衰协会发布了利尿剂在充血性心力衰竭中的应用的立场声明，绝大多数急性心力衰竭发作的特点是充血的症状和体征增多，治疗的目的是缓解充血状态，主要通过利尿剂的应用。本文主要内容涉及利尿剂在充血性心力衰竭中的应用，包括临床评估，利尿剂的应用以及常见电解质紊乱的管理。

中文标题：

2019 ESC立场声明：利尿剂在充血性心力衰竭中的应用

英文标题：

The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology.

发布机构：

欧洲心脏病学会

发布日期：

2019-01-01

简要介绍：

2019年1月，欧洲心脏病学会(ESC)心衰协会发布了利尿剂在充血性心力衰竭中的应用的立场声明，绝大多数急性心力衰竭发作的特点是充血的症状和体征增多，治疗的目的是缓解充血状态，主要通过利尿剂的应用。本文主要内容涉及利尿剂在充血性心力衰竭中的应用，包括临床评估，利尿剂的应用以及常见电解质紊乱的管理。 

拓展指南：与心力衰竭相关指南：

相关资料下载：
[AttachmentFileName(sort=100, fileName=2019 ESC立场声明：利尿剂在充血性心力衰竭中的应用)] GetToolGuiderByIdResponse(projectId=1, id=d2bc91c001686954, title=2019 ESC立场声明：利尿剂在充血性心力衰竭中的应用, enTitle=The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology., guiderFrom=Eur J Heart Fail. 2019 Jan 1., authorId=null, author=, summary=2019年1月，欧洲心脏病学会(ESC)心衰协会发布了利尿剂在充血性心力衰竭中的应用的立场声明，绝大多数急性心力衰竭发作的特点是充血的症状和体征增多，治疗的目的是缓解充血状态，主要通过利尿剂的应用。本文主要内容涉及利尿剂在充血性心力衰竭中的应用，包括临床评估，利尿剂的应用以及常见电解质紊乱的管理。 , cover=, journalId=null, articlesId=null, associationId=62, associationName=欧洲心脏病学会, associationIntro=是目前在欧洲居于首要地位的心脏病学会，会员超过70000人、提供更新指南、调查数据、组织学术会议，ESC年会是心血管领域最大的会议。下设5个分会（超声心动图学会、心律学会、心衰学会、预防与康复学会及介入学会）。提供指南较全面，按年份排列。现提供有手机板本。, copyright=0, guiderPublishedTime=Tue Jan 01 00:00:00 CST 2019, originalUrl=, linkOutUrl=, content=<div>2019年1月，欧洲心脏病学会(ESC)心衰协会发布了利尿剂在充血性心力衰竭中的应用的立场声明，绝大多数急性心力衰竭发作的特点是充血的症状和体征增多，治疗的目的是缓解充血状态，主要通过利尿剂的应用。本文主要内容涉及利尿剂在充血性心力衰竭中的应用，包括临床评估，利尿剂的应用以及常见电解质紊乱的管理。 </div> <div><br> </div>拓展指南：<strong>与<font color=red>心力衰竭</font>相关指南：</strong><br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=d83151c0016ea4fd" title="中国心力衰竭诊断和治疗指南2018" target=_blank>中国心力衰竭诊断和治疗指南2018</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=c02271c00166e94c" title="2018 ACR适宜性标准：疑似新发和已知的非急性心力衰竭" target=_blank>2018 ACR适宜性标准：疑似新发和已知的非急性心力衰竭</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=bac1f1c0016ae4e3" title="心力衰竭患者超滤治疗护理的专家共识" target=_blank>心力衰竭患者超滤治疗护理的专家共识</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=3b40a1c00162a1e8" title="2018 NHFA/CSANZ临床指南：心力衰竭的诊断和管理" target=_blank>2018 NHFA/CSANZ临床指南：心力衰竭的诊断和管理</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=734ae1c0015990e8" title="2018 ESC立场声明：晚期心力衰竭" target=_blank>2018 ESC立场声明：晚期心力衰竭</a></li> 更多信息请点击：<a href="http://www.medsci.cn/guideline/list.do?q=%E5%BF%83%E5%8A%9B%E8%A1%B0%E7%AB%AD" target=_blank>有关心力衰竭更多指南</a></ul>, tagList=[TagDto(tagId=3593, tagName=利尿剂), TagDto(tagId=7945, tagName=充血性心力衰竭)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=其他, guiderLanguage=0, guiderRegion=2, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=5476, appHits=447, showAppHits=0, pcHits=4099, showPcHits=1610, likes=149, shares=14, comments=5, approvalStatus=1, publishedTime=Sun Jan 13 23:26:38 CST 2019, publishedTimeString=2019-01-01, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Sun Jan 13 23:26:38 CST 2019, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 02:50:14 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2019 ESC立场声明：利尿剂在充血性心力衰竭中的应用)])
2019 ESC立场声明：利尿剂在充血性心力衰竭中的应用
下载请点击：
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=883567, encodeId=09cf88356e09, content=看看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210524/55f15b58d91d45c09faf0272721b59d8/b8f36c2def38403ab9fdabaae56a939c.jpg, createdBy=f0935399328, createdName=ms1000000302953060, createdTime=Tue Sep 08 10:49:47 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812465, encodeId=0a14812465d6, content=谢谢！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30442109581, createdName=1341f859b1m, createdTime=Sun Aug 23 19:29:01 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358184, encodeId=5d6935818425, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=57951685290, createdName=秀秀_smile, createdTime=Tue Jan 15 11:40:42 CST 2019, time=2019-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358087, encodeId=c66535808e15, content=谢谢分享，学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Mon Jan 14 09:18:52 CST 2019, time=2019-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358084, encodeId=9dab3580842d, content=总结的很好，很实用！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2019/01/02/06ff336a9fc3d156e1a30ee3d3448a83.jpg, createdBy=31f41577443, createdName=417735661, createdTime=Mon Jan 14 09:00:35 CST 2019, time=2019-01-14, status=1, ipAttribution=)]
    2020-09-08 ms1000000302953060

    看看

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=883567, encodeId=09cf88356e09, content=看看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210524/55f15b58d91d45c09faf0272721b59d8/b8f36c2def38403ab9fdabaae56a939c.jpg, createdBy=f0935399328, createdName=ms1000000302953060, createdTime=Tue Sep 08 10:49:47 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812465, encodeId=0a14812465d6, content=谢谢！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30442109581, createdName=1341f859b1m, createdTime=Sun Aug 23 19:29:01 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358184, encodeId=5d6935818425, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=57951685290, createdName=秀秀_smile, createdTime=Tue Jan 15 11:40:42 CST 2019, time=2019-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358087, encodeId=c66535808e15, content=谢谢分享，学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Mon Jan 14 09:18:52 CST 2019, time=2019-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358084, encodeId=9dab3580842d, content=总结的很好，很实用！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2019/01/02/06ff336a9fc3d156e1a30ee3d3448a83.jpg, createdBy=31f41577443, createdName=417735661, createdTime=Mon Jan 14 09:00:35 CST 2019, time=2019-01-14, status=1, ipAttribution=)]
    2020-08-23 1341f859b1m

    谢谢！

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=883567, encodeId=09cf88356e09, content=看看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210524/55f15b58d91d45c09faf0272721b59d8/b8f36c2def38403ab9fdabaae56a939c.jpg, createdBy=f0935399328, createdName=ms1000000302953060, createdTime=Tue Sep 08 10:49:47 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812465, encodeId=0a14812465d6, content=谢谢！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30442109581, createdName=1341f859b1m, createdTime=Sun Aug 23 19:29:01 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358184, encodeId=5d6935818425, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=57951685290, createdName=秀秀_smile, createdTime=Tue Jan 15 11:40:42 CST 2019, time=2019-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358087, encodeId=c66535808e15, content=谢谢分享，学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Mon Jan 14 09:18:52 CST 2019, time=2019-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358084, encodeId=9dab3580842d, content=总结的很好，很实用！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2019/01/02/06ff336a9fc3d156e1a30ee3d3448a83.jpg, createdBy=31f41577443, createdName=417735661, createdTime=Mon Jan 14 09:00:35 CST 2019, time=2019-01-14, status=1, ipAttribution=)]
    2019-01-15 秀秀_smile

    谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=883567, encodeId=09cf88356e09, content=看看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210524/55f15b58d91d45c09faf0272721b59d8/b8f36c2def38403ab9fdabaae56a939c.jpg, createdBy=f0935399328, createdName=ms1000000302953060, createdTime=Tue Sep 08 10:49:47 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812465, encodeId=0a14812465d6, content=谢谢！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30442109581, createdName=1341f859b1m, createdTime=Sun Aug 23 19:29:01 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358184, encodeId=5d6935818425, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=57951685290, createdName=秀秀_smile, createdTime=Tue Jan 15 11:40:42 CST 2019, time=2019-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358087, encodeId=c66535808e15, content=谢谢分享，学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Mon Jan 14 09:18:52 CST 2019, time=2019-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358084, encodeId=9dab3580842d, content=总结的很好，很实用！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2019/01/02/06ff336a9fc3d156e1a30ee3d3448a83.jpg, createdBy=31f41577443, createdName=417735661, createdTime=Mon Jan 14 09:00:35 CST 2019, time=2019-01-14, status=1, ipAttribution=)]
    2019-01-14 明月清辉

    谢谢分享，学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=883567, encodeId=09cf88356e09, content=看看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210524/55f15b58d91d45c09faf0272721b59d8/b8f36c2def38403ab9fdabaae56a939c.jpg, createdBy=f0935399328, createdName=ms1000000302953060, createdTime=Tue Sep 08 10:49:47 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812465, encodeId=0a14812465d6, content=谢谢！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30442109581, createdName=1341f859b1m, createdTime=Sun Aug 23 19:29:01 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358184, encodeId=5d6935818425, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=57951685290, createdName=秀秀_smile, createdTime=Tue Jan 15 11:40:42 CST 2019, time=2019-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358087, encodeId=c66535808e15, content=谢谢分享，学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Mon Jan 14 09:18:52 CST 2019, time=2019-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358084, encodeId=9dab3580842d, content=总结的很好，很实用！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2019/01/02/06ff336a9fc3d156e1a30ee3d3448a83.jpg, createdBy=31f41577443, createdName=417735661, createdTime=Mon Jan 14 09:00:35 CST 2019, time=2019-01-14, status=1, ipAttribution=)]
    2019-01-14 417735661

    总结的很好，很实用！

    0